melanoma skin cancer: will the drugs in the pipeline deliver?
TRANSCRIPT
1
Ranjith Gopinathan, Industry Analyst
Healthcare Practice
May 25,2010
Melanoma Skin Cancer: Will the Drugs in the Pipeline Deliver?
2
Disclaimer
• Frost & Sullivan takes no responsibility for the incorrect information supplied to us by manufacturers or users
• Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation
• No part of this Research Service may be given, lent, resold or disclosed to non-customers without written
permission
• Furthermore, no part may be reproduced, stored in a retrieval system, or transmitted in any form or by any
means, electronic, mechanical, photocopying, recording or otherwise, without the permission of the publisher
• For information regarding permission, write to:
Frost & Sullivan
4 Grosvenor Gardens
Sullivan House
London SW1W 0DH
The United Kingdom
© 2010 Frost & Sullivan. All rights reserved. This document contains highly confidential information and is the sole property of Frost & Sullivan.
No part of it may be circulated, quoted, copied or otherwise reproduced without the written approval of Frost & Sullivan.
3
Certification
• We hereby certify that the views expressed in this research service accurately reflect our views based on
primary and secondary research with industry participants, industry experts, end users, regulatory
organizations, financial and investment community, and other related sources
• In addition to the above, our robust in-house forecast & benchmarking models along with the Frost &
Sullivan Decision Support Databases have been instrumental in the completion this research service
• We also certify that no part of our analyst compensation was, is or will be, directly or indirectly, related
to the specific recommendations or views expressed in this service
4
Focus Points
Skin Cancer : Melanoma– Key Facts1
Patient Forecasts2
Market Drivers and Restraints3
Current Drug Therapies for Melanoma4
5 Revenue Forecasts
6 Pipeline Analysis - Melanoma
5
Skin Cancer : Melanoma– Key Facts
There are two main types of skin cancer:
•Melanoma
•Non-melanoma (Basal cell carcinoma, Squamous cell carcinoma)
Other types of Skin Cancer:
•Kaposi sarcoma (KS)
•Merkel cell carcinoma (MCC)
•Intraocular (Eye) Melanoma
•Dermatofibrosarcoma protuberans (DFSP)
•Sebaceous gland carcinoma (SGC)
• The incidence of melanoma at a global level is increasing faster than the other types of cancer, with an approximate
doubling of rates every 10 to 20 years in countries with Caucasian (light-skinned) populations.
• Melanoma is the second most common cancer in the age group of 15 to 34 years.
• Australia and New Zealand leads the world with world age-standardised rate between 30-40 cases per 100,000
population affected by skin cancer.
•Melanoma is curable when it is detected during the early stages. Surgery is common treatment for early stage melanoma.
•Melanoma is rare in non-white populations.
6
Patient Forecasts
7
Skin Cancer: Incidence and Mortality (World), 2006-2016
Note: The incidence post 2009 has
been calculated based on population statistics. The figures do not take into account changes in diagnosis or other external factors.
8
Melanoma: Incidence and Mortality (United States, EU, Australia), 2006-2016
9
Current Drug Therapies for Melanoma
Intron A (Interferon Alfa - 2B) Schering-PloughTreatment Area: Metastatic Melanoma
Approval Status: Approved in 1987 (US FDA)
Patent Expiry: 2002
Proleukin or Aldesleukin( IL-2, Interleukin 2) NovartisApproval Status: Approved in 1998 (US FDA)
Treatment Area: Metastatic melanoma
Chemotherapy
DTIC-Dome (Dacarbazine) Bayer
Approval Status: Approved in 1975 (US FDA)
Treatment Area: Metastatic melanoma
Generics: Available
10
Skin Cancer Therapeutics Market: Market Drivers Ranked in Order of Impact (World), 2010-2016
11
Skin Cancer Therapeutics Market: Market Restraints Ranked in Order of Impact (World), 2010-2016
12
Revenue Forecasts
13
Melanoma Therapeutics Market: Revenue Forecasts (World), 2006-2016
Note:• Future revenue potential of promising drug candidates which are currently in pipeline are also considered in the revenue forecasts.
• Many of the drugs for cancer are indicated for more than one therapeutic indication. Publicly available information tends to combine all indications when sales figures are reported. Therefore, estimations and primary research were used to arrive at the Melanoma therapeutics revenue forecasts. In addition, the revenue estimations have been cross-validated with the market participants.
14
Melanoma Therapeutics Market: Revenue Forecasts (United States), 2006-2016
15
Melanoma Therapeutics Market: Revenue Forecasts (European Union), 2006-2016
16
Melanoma Therapeutics Market: Revenue Forecasts (Rest-of-World), 2006-2016
17
Pipeline Analysis - Melanoma
Sheba Medical CenterAdoptive cell transfer (ACT) therapy
AntisomaAS1409
Bayer/ OnyxNexavar
NovartisGleevec (imatinib mesylate)
BioVex
Limited /Symbion Research
InternationalOncoVEX
Avax TechnologiesMvax
Abraxis BioScience/ AstraZenecaAbraxane
Genta / Sanofi-AventisGenasense (oblimersen)
Vical/ AnGesAllovectin-7
Roche/ PlexxikonPLX4032
Bristol-Myers Squibb/ MedarexIpilimumab
DevelopersDrug Name
Note: The above drugs pipeline list includes only, some of the most promising drugs in development and may not necessarily include all (promising) drugs in development for melanoma.
18
Next Steps
� Request a strategic approach document for a Growth Partnership Service or Growth Consulting Service to support you and your team to accelerate the growth of your company.
([email protected]) +44 (0)20 7343 8383
� Join us at our annual Growth, Innovation and Leadership 2010: A Frost & Sullivan Global Congress on Corporate Growth London, United Kingdom (www.gil-global.com)
� Register for the next Chairman’s Series on Growth:
Accelerating Growth Through Vertical Market Expansion: A How-To Primer16 June 2010 10:00 AM BST (www.frost.com/growthEU)
� Register for Frost & Sullivan’s Growth Opportunity Newsletter and keepabreast of innovative growth opportunities (www.frost.com/news)
19
Your Feedback is Important to Us
Growth Forecasts?
Competitive Structure?
Emerging Trends?
Strategic Recommendations?
Other?
Please inform us by taking our survey.
What would you like to see from Frost & Sullivan?
20
Find us @Frost_Sullivan on Twitter
Frost & Sullivan on Twitter and Facebook
Become a fan of Frost & Sullivan on Facebook
21
For Additional Information
Katja Feick
Corporate Communications
Healthcare
0049 (0) 69 7703343
Noel Anderson
European Vice President
New Business Development
+44 (0)207 343 8389
Siddharth SahaProgram DirectorHealthcare – Medical Technologies+44 (0) 207 343 [email protected]